5.6 Diabetic Kidney Disease, Neuropathy and Foot Risk
Key Takeaways
Use eGFR and ACR together and confirm persistent kidney abnormalities after transient triggers have resolved.
Evaluate rapid renal deterioration or atypical urinary findings for causes in addition to diabetes.
Check protective sensation and circulation. A hot swollen neuropathic foot requires urgent assessment and protection even with little pain.
Detect kidney disease and ask whether diabetes explains the findings
Estimate glomerular filtration rate (eGFR) and measure urinary albumin-to-creatinine ratio (ACR). These capture different aspects of kidney risk. Use a spot sample, with a first morning sample useful for confirming an unexpected result. ADA 2026 recommends checking both at least annually in all adults with type 2 diabetes and in type 1 diabetes from five years after diagnosis. Once CKD is established, monitoring frequency depends on risk and the care plan. In Ireland the HSE integrated model allocates follow-up and escalation across primary care, community specialist and hospital services.
A single ACR is variable. Recent exercise, infection, fever, marked hyperglycaemia, severe hypertension, menstruation or heart failure can increase albumin excretion transiently. Confirm a raised value when the person is stable. For persistent moderately or severely elevated albuminuria, ADA uses two abnormal results among three specimens collected over three to six months. Diagnose CKD from persistent abnormalities or other evidence of chronicity. Normal eGFR does not exclude CKD with persistent albuminuria, and reduced eGFR in diabetes can occur without high ACR. A rapid fall in eGFR, red-cell casts, rapidly rising proteinuria or a nephrotic presentation suggests an additional or alternative cause and warrants prompt renal assessment. In type 1 diabetes, lack of retinopathy can also make typical diabetic kidney disease less likely. A simultaneous acute change requires assessment for AKI.
Use the GFR and ACR categories together to plan follow-up. Review glycaemic and blood pressure management, cardiovascular risk, medicine interactions and NSAID exposure. An ACE inhibitor or ARB is used in eligible patients with diabetes, hypertension and albuminuria. Monitor potassium and creatinine when starting or titrating it. For type 2 diabetes with CKD, an appropriate SGLT2 inhibitor can reduce kidney and cardiovascular events when current renal and product prescribing criteria permit. Check the agent-specific starting limits and sick-day or perioperative precautions. Refer when the trajectory, atypical findings, complications or risk warrant specialist review.
HSE integrated type 2 diabetes model · ADA 2026 kidney risk recommendations · KDIGO diabetes and CKD guidance · KDIGO 2024 CKD guideline.
Use a scheduled diabetes review to prevent complications
In stable type 2 diabetes, agree an individual glycaemic goal and review trends, medicines, adverse effects and hypoglycaemia. Measure blood pressure and assess lipids and cardiovascular risk. Review kidney function and urine albumin-to-creatinine ratio as indicated, foot risk and access to Diabetic RetinaScreen. Check smoking, nutrition, physical activity and patient priorities. Offer education and agree follow-up, who will act on results and when earlier assessment is warranted. An acceptable HbA1c does not remove the need to assess silent complications or cardiovascular risk.
In Ireland, the integrated model describes coordinated general practice, community and hospital diabetes care according to need. Active foot problems, significant progression of kidney disease and recurrent severe hypoglycaemia each change the urgency or team required. Review the management plan when frailty, treatment burden or patient priorities change.
HSE integrated model of care for type 2 diabetes · HSE Diabetes Cycle of Care
An adult with type 2 diabetes, previously normal ACR and normal, stable eGFR, has a urine ACR of 8 mg/mmol during a febrile symptomatic urinary infection. There are no casts, nephrotic features or acute kidney deterioration. What is the most appropriate response to this result?
Confirm persistent diabetic kidney disease from this sample alone
Dismiss the raised albumin excretion because the eGFR is normal
Repeat ACR when the infection has resolved and assess persistence together with eGFR
Arrange emergency kidney biopsy on the basis of the ACR alone
Assess neuropathy and distinguish a high-risk foot from active disease
Distal symmetrical polyneuropathy often begins in the feet. Ask about burning pain, tingling, numbness, sleep disturbance or falls. Test vibration with a 128 Hz tuning fork, and test pinprick or temperature when assessing small-fibre function. A 10 g monofilament helps detect loss of protective pressure sensation, which can be present even without pain. Inspect skin and nails, check for deformity, wounds and callus, and assess footwear and both dorsalis pedis and posterior tibial pulses. Atypical asymmetry, rapid progression or predominant weakness prompts evaluation for other causes. Review alcohol, thyroid dysfunction and B12 deficiency, including with long-term metformin, as the context suggests. Ask about postural symptoms, bladder or sexual dysfunction and early satiety when autonomic involvement is suspected, and assess common alternatives.
| Foot finding | Initial plan under the Irish care model |
|---|---|
| Intact skin, preserved sensation and circulation, and no other risk markers | Routine structured foot assessment and prevention advice. |
| Sensory loss, vascular impairment, deformity or previous injury such as ulceration or amputation | Use the HSE risk classification and arrange foot protection or specialist follow-up according to the assessment. |
| A new ulcer, spreading infection, critical ischaemia or unexplained unilateral hot, red, swollen foot | Active foot disease needs urgent assessment. The HSE pathway calls for referral to the multidisciplinary foot team within 24 hours and review within 24 hours of referral or the next working day. Escalate immediately for systemic illness or a threatened limb. For suspected active Charcot change, protect and offload promptly while arranging urgent specialist review. |
In a neuropathic foot, active Charcot neuro-osteoarthropathy can cause warmth and swelling with little pain or no break in the skin. Evaluate for infection, fracture, vascular disease and other causes. A normal initial X-ray cannot exclude early Charcot disease. The IWGDF recommends prompt immobilisation and offloading while definitive assessment proceeds, and MRI when radiographs are normal and suspicion remains. Avoid relying on absent pain or an apparently reassuring radiograph.
HSE diabetic foot model of care · ADA 2026 neuropathy and foot care · IWGDF Charcot neuro-osteoarthropathy guideline.
Treat established painful distal neuropathy
Once examination supports distal symmetrical neuropathy, agree goals for sleep and function and choose treatment based on comorbidity. ADA 2026 supports initial use of selected gabapentinoids, SNRIs, tricyclic antidepressants or sodium-channel blockers. Check the exact medicine's licence, renal requirements and interactions. Gabapentinoids can cause dizziness or somnolence and need renal dosing. Tricyclic antidepressants can aggravate orthostasis or urinary retention. Duloxetine is authorised for diabetic peripheral neuropathic pain in adults under the EU Cymbalta label and is contraindicated with creatinine clearance below 30 mL/min. Review whether treatment meaningfully helps and switch class if benefit is insufficient or adverse effects limit use. Avoid routine opioids for this indication. Pain relief does not restore protective sensation. Continue foot protection and follow-up.
ADA 2026 recommendation 12.22 · EU Cymbalta product information.
An adult with diabetes and bilateral loss of protective sensation has a newly warm, red, swollen foot. The skin is intact, pedal pulses are palpable and he has little pain. There is no systemic illness. The initial radiograph shows no fracture or obvious deformity. What is the most appropriate next step?
Protect and offload the foot and arrange urgent diabetic foot assessment for possible active Charcot disease
Permit unrestricted walking because the radiograph is normal
Defer review until an ulcer or severe pain develops
Arrange routine yearly foot review only
A patient with stable type 2 diabetes takes treatment regularly and has reached an individual HbA1c goal. He has missed his routine review for over a year. What should the practice arrange?
Check HbA1c only because other screening is unnecessary at target
Arrange a coordinated review of cardiovascular and renal risk, feet, retinal screening, medicines and goals
Use repeated urine glucose alone to screen for kidney complications
Wait for painful feet or blurred vision before arranging further review
An adult with established painful diabetic polyneuropathy has poor sleep from bilateral burning feet. There is no new wound, redness, swelling or evidence of ischaemia. Renal function is normal, blood pressure is controlled and no hepatic contraindication or interacting drug is identified. Which plan is suitable?
Start long-term tramadol as routine first-line therapy
Stop daily foot checks once pain settles
Start an oral NSAID to restore protective sensation
Consider duloxetine after a full medicine review, agree functional goals and continue foot protection
Sections you finish are checked off in the contents.